P.A. Hertzen Moscow Oncology Research Institute - Academic Profile

Publications

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini , Elizabeth R. Plimack , V.P. Stus +24 more

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progress...

2019 New England Journal of Medicine 3200 citations

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer , B. Yа. Alekseev , Sun Young Rha +35 more

Lenvatinib plus pembrolizumab was associated with significantly longer progression-free survival and overall survival than sunitinib. (Funded by Eisai and Merck Sharp and Dohme;...

2021 New England Journal of Medicine 1597 citations

Affiliated Researchers

B. Yа. Alekseev

P.A. Hertzen Moscow Oncology Research Institute

Institution Info

Type: facility
Country: RU
Publications: 2
Citations: 4,797

External Links

Identifiers

ROR: https://ror.org/04rbazs75